AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival
Research output: Contribution to journal › Journal article › Research › peer-review
Final published version, 524 KB, PDF document
Katja Kemp Jacobsen, Jakob Sidenius Johansen, Anders Mellemgaard, Stig Egil Bojesen
BACKGROUND: Prior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer subtypes). It is unknown if AHRR (cg05575921) hypomethylation is associated with reduced survival among lung cancer patients.
METHODS: In bisulfite treated leukocyte DNA from 465 lung cancer patients from the Copenhagen prospective lung cancer study, we measured AHRR (cg05575921) methylation. 380 died during max follow-up of 4.4 years. Cox proportional hazard models were used to analyze survival as a function of AHRR (cg05575921) methylation.
RESULTS: We observed the expected inverse correlation between cumulative smoking and AHRR methylation, as methylation (%) decreased (Coefficient -0.03; 95% confidence interval, -0.04- -0.02, p = 8.6x10-15) for every pack-year. Cumulative smoking > 60 pack-years was associated with reduced survival (hazard ratio and 95% confidence interval 1.48; 1.05-2.09), however, AHRR (cg05575921) methylation was not associated with survival when adjusted for sex, body mass index, smoking status, ethnicity, performance status, TNM Classification, and histology type of lung cancer.
CONCLUSION: AHRR (cg05575921) methylation is linked to smoking but does not provide independent prognostic information in lung cancer patients.
|Number of pages||13|
|Publication status||Published - 2019|